University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (afternoon panel discussion session)
Restricted accessOtherFirst published online August, 2015
University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (afternoon panel discussion session)
ZeeJXieSX. Assessing treatment effects with surrogate survival outcomes using an internal validation subsample. Clin Trials2015; 12: 333–341.
2.
JackCRJrAlbertMSKnopmanDS. Introduction to the recommendations from the National Institute on Aging—Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 257–262 (Also, Alzheimer’s Association and the National Institute on Aging (NIA), http://www.alz.org/research/diagnostic_criteria/ (2015, accessed 7 May 2015)).
3.
KattanMGerdsTA. Comparison of two ordinal prediction models: a cancer staging system example. Clin Trials2015; 12: 342–347.
4.
HuangY. Identifying optimal biomarker combinations for treatment selection through randomized controlled trials. Clin Trials2015; 12: 348–356.
5.
WeisbergHIPontesVP. Post hoc subgroups: anathema or analytics?Clin Trials2015; 12: 357–364.
6.
WeinerMWVeitchDPAisenPS. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement2012; 8: S1–S68.
7.
ShawLMVandersticheleHKnapik-CzajkaM. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol2009; 65: 403–413.
8.
VickersAJElkinEB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making2006; 26: 565–574.
